The Influence of Trained Immunity in COVID-19 Vaccinated Individuals
NCT05705180 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2023-01-30
Summary
The concept of trained immunity defines the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and leads to an altered response towards a second challenge after return to a non-activated state and is characterized by several markers, such as specific cytokines, activation markers of innate immune cells and epigenetic modifications, e.g. H3K4me3. Vaccinations have been shown to induce trained immunity and to have heterologous effects on other infections or vaccinations. A recent article showed, that individuals who had received recombinant adjuvanted zoster vaccine (RZV) before the pandemic had a 16% lower risk of COVID-19 diagnosis and a 32% lower risk of hospitalization suggesting a protective heterologous effect of RVZ on COVID19 infections. So far, the mechanisms behind these add-on benefits of RZV vaccination are on the hypothetical level and need further experimental evidence.
Therefore, we aim to investigate the specific humoral and cellular immune response towards COVID-19 vaccine in healthy individuals who were exposed to RZV 1 to 12 months before COVID-19 vaccination compared to individuals who did not receive RZV before. Particular emphasis is layed on COVID-19 vaccine non-responders and individuals with breakthrough infections indicating lower vaccine efficacy compared to those who had no breakthrough infection.
The primary objective is the cytokine profile of spike protein-stimulated T, NK and NKT cells. Spike protein stimulated T, NK and NKT cells are characterized by cell surface markers, transcription factor expression, chemokine receptor expression, activation and proliferation markers and by their lineage-specific cytokine pattern. CD14+ monocytes are magnetically isolated and further characterized by cell-culture experiments imitating a training and resting period after stimulation. Epigenetic modifications by methylation of CpG regions are assessed at promoter, enhancer and regulatory gene regions of immune cell characteristic transcription factors by bisulfite conversion and pyrosequencing. Chromatin immunoprecipitation and ChIP-seq will be performed for analysis H3K4me3 associated with trained immunity. Humoral and cellular reactivity to spike protein is analyzed by adapted ELISA and neutralisation assays and by ELISpot and flow cytometry, respectively, and correlated.
From our findings we expect to learn about the role of previous RZV on immunogenicity and efficacy of COVID-19 vaccination and whether mechanisms of trained immunity play a role for better responses towards COVID-19 vaccination.
Conditions
- Zoster Varicella
- Vaccination; Infection
Interventions
- BIOLOGICAL
-
recombinant adjuvanted zoster vaccine
vaccination with recombinant adjuvantes zoster vaccine
Sponsors & Collaborators
-
Wuerzburg University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2023-12-01
- Completion
- 2024-12-01
Countries
- Germany
Study Locations
More Related Trials
-
Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers
NCT04996238 ·Status: COMPLETED ·Phase: NA
-
Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial
NCT04368013 ·Status: ACTIVE_NOT_RECRUITING
-
Optimal Timing of Zoster Vaccine After Zoster Illness
NCT02704572 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500
NCT00518492 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
NCT05408299 ·Status: UNKNOWN
-
Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations
NCT04853004 ·Status: ACTIVE_NOT_RECRUITING
-
Post-Vaccination Biological Collection
NCT03875703 ·Status: RECRUITING
-
Biomarkers of Trained Immunity Following MMR Vaccination
NCT04646239 ·Status: COMPLETED
-
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
NCT05226390 ·Status: TERMINATED ·Phase: PHASE1
-
Immune Response Following COVID-19 Vaccination
NCT04736524 ·Status: UNKNOWN
-
Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.
NCT05228912 ·Status: COMPLETED
-
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
NCT00886613 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
NCT00397943 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
NCT01527383 ·Status: COMPLETED ·Phase: PHASE2
-
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
NCT01600079 ·Status: COMPLETED
-
Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
NCT04895449 ·Status: COMPLETED ·Phase: PHASE1
-
Description of the Immune Response to Yellow Fever Vaccination
NCT06718127 ·Status: RECRUITING ·Phase: NA
-
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
NCT06189040 ·Status: COMPLETED ·Phase: PHASE4
-
Month 30 & 42 Extension Studies of CRD-004 Primary Study
NCT00492648 ·Status: COMPLETED ·Phase: PHASE2
-
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
NCT01911065 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
NCT07321808 ·Status: RECRUITING
-
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
NCT02979639 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
NCT03439657 ·Status: COMPLETED ·Phase: PHASE3
-
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older
NCT07311148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
NCT06961721 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4